Logo

Third Wave Shares Climb 5 Percent on HPV Settlement

Jan 13, 2006

NEW YORK, Jan. 13 (GenomeWeb News) - Shares in Third Wave were up 5.26 percent, or $.17, at $3.40 in mid-afternoon trading today after the company said it settled its patent-infringement suit against Digene.

 

As GenomeWeb News reported this morning, Third Wave and Digene agreed to not sue each other over human papillomavirus products patents for one year. The settlement does not include any license or payment by either company.

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.